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Abstract The oxygen consumption of leukocyte mitochondria
of both healthy donors and leukemic patients was tested by using
different respiratory substrates. The results indicate that
pyruvate could not be utilized by mitochondria of normal
leukocytes, whereas mitochondria of leukemic leukocytes could
use pyruvate as a good respiratory substrate. A search for the
possible presence of pyruvate dehydrogenase complex (PDC) in
leukocytes indicates that this enzyme is apparently absent in
mitochondria of normal leukocytes but is quite active in
mitochondria of leukemic leukocytes. The absence of PDC in
normal leukocyte mitochondria can explain the phenomenon of
significant aerobic glycolysis that has been observed in normal
leukocytes.
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1. Introduction
It has been known for a long time that malignant cells
produce lactic acid from glucose at an abnormally high rate
even in the presence of oxygen which normally inhibits this
process [1,2]. However, several normal tissues such as retina,
intestinal mucosa, kidney medulla [3], and normal leukocytes
[4] also exhibit a similar phenomenon. We have recently
studied the e¡ect of methylglyoxal, a potent anticancer agent,
on the mitochondrial respiration of human leukocytes, both
normal and malignant, with di¡erent respiratory substrates
[5]. During the course of this study, we made an interesting
observation: pyruvate, which is a usual substrate of mito-
chondrial respiration, cannot be utilized by mitochondria of
normal leukocytes, whereas pyruvate as usual is oxidized by
mitochondria of leukemic leukocytes. On further investiga-
tion, we observed that PDC, the enzyme necessary for the
oxidation of pyruvate, is absent in the mitochondria of nor-
mal leukocytes. This absence of PDC in normal leukocytes
can explain the phenomenon of signi¢cant aerobic glycolysis
in these cells.
2. Materials and methods
2.1. Chemicals and blood
All the biochemicals and the mitochondrial respiratory inhibitors
rotenone and malonate were purchased from Sigma Chemical Co., St.
Louis, MO, USA. Other chemicals were of analytical grade and were
obtained from local manufacturers.
Blood of leukemic patients (su¡ering from chronic myeloid leuke-
mia or acute myeloid leukemia or chronic lymphocytic leukemia or
acute lymphocytic leukemia) were collected from the hematology unit
of the hospital. Patients with chronic myeloid leukemia were selected
for this study if their peripheral leukocyte count ranged from 90 000
to 150 000 cells/ml with almost 95% of these cells of the leukemic
series. For the other types of leukemia, patients were selected with
leukocyte counts of more than 25 000 cells/ml. Normal blood was
from healthy donors. For collection of blood, informed consent was
obtained from the donors. The blood was brought to the laboratory
at ambient temperature and the experiments were started within 1 h
after withdrawal of blood.
For respiratory studies, blood was collected from 10 healthy male
donors (26^40 years old) and nine male and ¢ve female patients (9^33
years old). For the assay of PDC in leukocyte preparations, blood was
collected from 10 healthy male donors (25^45 years old) and ¢ve male
and one female patients (18^50 years old). We have observed that age
and sex of donors have no in£uence on the experimental results.
Results presented in this paper for leukemic blood were obtained
from leukocytes of patients with chronic myeloid leukemia. Similar
results were also obtained with other types of leukemic leukocytes.
2.2. Preparation and assay of enzymes
Leukocytes were isolated from whole blood and mitochondria were
prepared and the respiration was measured as described previously [5].
The mitochondrial suspensions were sonicated for a total period of
2 min (30 s each, 4 times), and centrifuged at 30 000Ug for 30 min.
After discarding the precipitate, the supernatant (approximately 2.3 ml
from 50 ml of whole blood) was used for PDC activity.
2.3. PDC from goat heart
All operations were at 0^4‡C. 5 g of goat heart tissue obtained from
a local slaughterhouse was homogenized in a loosely ¢tting Potter-
Elvehjem homogenizer with 15 ml of 0.25 sucrose, 25 mM potassium
phosphate bu¡er, pH 7.4 and 0.2 mM EDTA. The homogenate was
centrifuged at 2000Ug for 10 min and the pellet was discarded. The
supernatant was centrifuged at 22 000Ug for 10 min and the super-
natant was discarded. The pellet was suspended in 0.25 M sucrose
containing 25 mM potassium phosphate bu¡er pH 7.4 and centri-
fuged at 30 000Ug for 10 min. The precipitate was washed twice
and was suspended in the same bu¡er and sonicated for 2 min (30 s
each, 4 times). The sonicated material was centrifuged at 30 000Ug
for 10 min and after discarding the precipitate, the supernatant (ap-
proximately 2.5 ml) was used for PDC activity.
2.4. Arylamine acetyltransferase
This enzyme was partially puri¢ed from pigeon liver. All operations
were at 0^4‡C. 2 g of pigeon liver was homogenized in a Potter-
Elvehjem homogenizer with six volumes of 25 mM sodium phosphate
bu¡er, pH 7.4 containing 2 mM L-mercaptoethanol. The homogenate
was centrifuged at 10 000Ug for 10 min and the precipitate was dis-
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carded. To the supernatant (10 ml), 1 ml of 1% protamine sulfate was
added dropwise. After standing for 10 min, the suspension was cen-
trifuged as above and the precipitate was discarded. The supernatant
was subjected to (NH4)2SO4 fractionation. The enzyme fraction which
appeared at 40^60% (NH4)2SO4 saturation was subjected to dialysis
against 25 mM Na-phosphate bu¡er, pH 7.4 containing 2 mM L-
mercaptoethanol. This enzyme preparation which was free of any
PDC contamination was used as arylamine acetyltransferase activity.
2.5. Assay of enzymes and estimation of protein
The assay of PDC was done according to the method of Coore et
al. with minor modi¢cations [6]. The enzyme was assayed by coupling
with arylamine acetyltransferase [7] and monitoring the change in
extinction at 420 nm due to acetylation of p-nitroaniline by the ace-
tyl-CoA formed in the PDC reaction. The assay mixture contained in
a total volume of 1 ml, 50 Wmol of sodium phosphate bu¡er, pH 7.9,
1 Wmol of NAD, 0.01 Wmol of thiamine pyrophosphate, 1 Wmol of
MgCl2, 2 Wmol of pyruvate, 0.16 Wmol of p-nitroaniline, 0.1 unit of
arylamine acetyltransferase; the reaction was started by the addition
of 0.2 Wmol of coenzyme A. Appropriate control was made with
boiled PDC or omitting coenzyme A in the incubation mixture. We
could not assay PDC activity by monitoring the formation of NADH
due to the presence of signi¢cant NADH oxidizing activity in our
enzyme preparation.
One unit activity of PDC is de¢ned as the amount of the enzyme
required to cause a decrease in absorbance of 0.57 due to acetylation
of 0.1 Wmol of p-nitroaniline. Speci¢c activity is de¢ned as units of
activity per mg of protein.
The assay mixture for arylamine acetyltransferase contained in a
total volume of 1 ml, 100 Wmol of sodium phosphate bu¡er, pH 6.8,
0.16 Wmol of p-nitroaniline, 0.15 Wmol of acetyl-CoA and the requisite
amount of the enzyme. The decrease in absorbance at 420 nm was
monitored. The absorbance of 0.1 Wmol of p-nitroaniline at 420 nm is
0.570. One unit of arylamine acetyltransferase activity was de¢ned as
the amount of the enzyme required to acetylate 1 Wmol of p-nitroani-
line per minute under the standard assay conditions.
Protein was estimated with bovine serum albumin as standard by
the method of Lowry et al. [8].
3. Results
3.1. Oxygen uptake by mitochondria of normal leukocytes with
di¡erent respiratory substrates
In Fig. 1, trace a shows that malate plus pyruvate, which
are typical respiratory substrates for other normal cellular
mitochondria, could not be used by normal leukocyte mito-
chondria. But when NAD was added to the system, a signi¢-
cant respiratory rate was observed. Moreover, normal leuko-
cyte mitochondria consumed oxygen at a signi¢cant rate with
only malate in the presence of NAD and pyruvate had no
e¡ect on the rate of oxygen uptake with malate and NAD
as respiratory substrates (trace b). Trace c shows that in the
absence of malate, pyruvate could not be used as respiratory
substrate even in the presence of NAD, but when malate was
added to the system a rapid rate of oxidation began, and this
respiration could as usual be inhibited by the mitochondrial
complex I-speci¢c inhibitor rotenone. Succinate could elicit a
moderately higher rate of respiration by normal leukocyte
mitochondria in the absence of NAD and this succinate-de-
pendent respiration could as usual be inhibited by malonate
(trace d). Moreover, NAD has no e¡ect on succinate-depend-
ent respiration (data not presented).
All these results strongly suggest that pyruvate could not be
utilized by normal leukocyte mitochondria.
3.2. Oxygen consumption of mitochondria of leukemic
leukocyte with various respiratory substrates
In Fig. 2, trace a shows that, in contrast to normal leuko-
cyte mitochondria, mitochondria of leukemic leukocytes could
oxidize pyruvate plus malate at a fairly high rate even in the
absence of NAD, and NAD has a little stimulatory e¡ect on
this malate plus pyruvate-dependent respiration. Malate in the
presence of NAD could also be oxidized, but pyruvate had a
substantial stimulatory e¡ect (trace b). Trace c shows that
pyruvate in the presence of NAD could not elicit any respi-
ratory rate, but when malate was added to the system, a rapid
rate of oxygen consumption was observed. The FAD-linked
substrates succinate (trace d) and K-glycerophosphate (not
presented) could be oxidized at a much faster rate and the
oxidation of succinate could be conveniently blocked by mal-
onate, a known inhibitor of succinic dehydrogenase (complex
II). The respiration of leukemic leukocyte mitochondria with
K-oxoglutarate, succinate and K-glycerophosphate was not af-
fected by NAD (not presented).
3.3. The status of PDC in normal and leukemic leukocyte
mitochondria
All the results presented above strongly suggest that pyru-
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Fig. 1. Oxygen uptake by mitochondria (M) of normal leukocytes
with di¡erent respiratory substrates. The direct oxygraph tracings of
a typical experiment are shown. Addition of di¡erent substrates and
inhibitors is indicated in the respective tracings. The numbers out-
side parentheses and the numbers within parentheses along the trac-
ings represent the rate of oxygen consumption (ng atoms of oxygen/
min and ng atoms of oxygen/min/mg of protein rerspectively). In
each case, in a control set of experiments in which no inhibitor was
added, mitochondria can consume oxygen at a linear rate for a peri-
od of at least 30 min. The total amounts of oxygen and mitochon-
drial protein present in the incubation mixture were approximately
990 ng atoms and 0.8 mg respectively.
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vate could not be oxidized by mitochondria of normal leuko-
cytes, whereas mitochondria of leukemic leukocytes, like the
mitochondria of other normal cells, could use pyruvate as a
respiratory substrate. This interesting ¢nding prompted us to
investigate the status of PDC in both normal and leukemic
leukocyte mitochondria. It is well known that pyruvate gen-
erated in glycolysis is transported into mitochondria and is
oxidized through the citric acid cycle after being converted
to acetyl-CoA by PDC.
The results of our investigation indicate that pyruvate could
not be converted to acetyl-CoA by a crude mitochondrial
preparation of normal leukocytes, whereas a mitochondrial
preparation of leukemic leukocytes could convert pyruvate
to acetyl-CoA at a substantial rate and this rate is comparable
with the activity of PDC present in the crude preparation of
goat heart mitochondria (Fig. 3).
It is well known that phosphorylation of the pyruvate de-
hydrogenase component of PDC inactivates the enzyme com-
plex and dephosphorylation reactivates the complex [9]. The
phosphorylated (inactive) enzyme complex is reactivated in
the presence of Mg2 [10]. However, we could not obtain
PDC activity in normal leukocyte mitochondrial preparations
even after incubation of these preparations with Mg2.
4. Discussion
As mentioned before, rapidly growing malignant cells have
a high rate of aerobic glycolysis and this phenomenon has
been considered by many biochemists to be a fundamental
feature of malignant aberration. However, it has also been
observed that several non-cancerous tissues such as retina,
normal leukocytes, kidney medulla, etc. have appreciable
aerobic glycolysis [3,4]. Several attempts have been made to
provide an explanation for the aerobic glycolysis observed in
these cells. The results presented in this paper convincingly
demonstrate that the enzyme PDC is absent in normal leuko-
cytes but is present in leukemic leukocytes. Due to the absence
of PDC in normal leukocytes, the pyruvate that is generated
in the glycolytic pathway cannot enter into the citric acid
cycle. As a result, the active L-lactic dehydrogenase which is
present in the cellular pool converts pyruvate to L-lactic acid
resulting in appreciable aerobic glycolysis. The present study,
however, has not investigated the status of PDC in di¡erent
varieties of normal leukocytes. But we can assume that the
absence of PDC in neutrophils and also possibly in lympho-
cytes can account for the appreciable lactic acid formation in
total leukocytes, considering the relative number of these cells
present.
One peculiar property of normal leukocyte mitochondria is
that they cannot oxidize malate without the addition of NAD
[11]. Like the previous work of Foster and Terry [11] with
normal human leukocyte mitochondria, we observed that
the rate of oxidation with only malate was very feeble, but
when NAD was added to the incubation mixture the rate was
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Fig. 3. Formation of p-nitroacetanilide by PDC- or acetyl-CoA-de-
pendent acetylation of p-nitroaniline. a and F represent acetylation
by a crude PDC preparation from leukemic leukocytes; b and O
that by a crude preparation from leukocytes isolated from the blood
of healthy donors; E that by PDC partially puri¢ed from goat
heart; formation of p-nitroacetanilide by the addition (indicated by
s) of either crude PDC from goat heart or known acetyl-CoA (0.1
Wmol) to the incubation mixture containing crude preparation from
normal leukocytes is represented by R and U respectively. The
numbers on the curve represent mg of protein used in the assay
mixtures.
Fig. 2. Oxygen uptake by mitochondria of leukemic leukocytes with
di¡erent respiratory substrates. The details are similar to the legends
of Fig. 1 except that the incubation mixtures contained approxi-
mately 0.35 mg of mitochondrial protein for tracings a, b and c and
0.5 mg of mitochondrial protein for tracing d.
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increased substantially. In several previous studies on the ox-
idation of di¡erent substrates by plant mitochondria, NAD
had been added in the incubation mixture which resulted in an
appreciable increase in the rate of oxidation of these sub-
strates [12,13].
The results presented in this paper also illuminate the in-
terrelationship of two energy (ATP) producing processes,
namely glycolysis and mitochondrial respiration, in normal
and malignant cells. In several recent publications from our
laboratory, we have provided strong experimental evidence
and theoretical arguments which suggest that excessive ATP
formation in cells may lead to malignancy [5,14,15]. In con-
trast to the established idea, in malignant cells, not only gly-
colysis is enhanced, but mitochondrial respiration is also ele-
vated so as to favor excessive ATP formation. From the
results presented in this paper we can assume that in normal
leukocytes the gene responsible for PDC is somehow not ex-
pressed, whereas during the process of malignant transforma-
tion the PDC gene is expressed and the enzyme is synthesized.
The presence of this enzyme in leukemic leukocytes further
strengthens the oxidative machinery of the cells.
The multienzyme PDC has been puri¢ed from di¡erent
sources and the mechanism of interaction of di¡erent enzyme
components has been studied to understand the regulation of
£ux of pyruvate through this enzyme complex. It is generally
assumed that the PDC reaction is controlled mainly by a
highly regulated phosphorylation/dephosphorylation cycle
(see [9,10,16] and the references cited therein). But our studies
have implicated this enzyme complex in malignant aberra-
tions. It will be interesting to study the expression of the
PDC gene during malignant transformation at least in human
leukocytes.
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